IN2014CN03950A - - Google Patents

Info

Publication number
IN2014CN03950A
IN2014CN03950A IN3950CHN2014A IN2014CN03950A IN 2014CN03950 A IN2014CN03950 A IN 2014CN03950A IN 3950CHN2014 A IN3950CHN2014 A IN 3950CHN2014A IN 2014CN03950 A IN2014CN03950 A IN 2014CN03950A
Authority
IN
India
Prior art keywords
terpenoid
ophthalmological
polymer compound
inhibitory activity
aqueous composition
Prior art date
Application number
Inventor
Yasuko Matsumura
Chinatsu Furumiya
Masashi Itoh
Original Assignee
Rohto Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharma filed Critical Rohto Pharma
Publication of IN2014CN03950A publication Critical patent/IN2014CN03950A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Abstract

The present invention provides an ophthalmological aqueous composition containing (A) a terpenoid (B) zinc chloride and (C) at least one type selected from a group consisting of a cellulose polymer compound a vinyl polymer compound polyethylene glycol and a dextran. This ophthalmological aqueous composition: is capable of suppressing a decrease over the long term in the amount of the terpenoid contained by suppressing adsorption of the terpenoid by a container; and furthermore has excellent histamine release inhibitory activity rheum inhibitory activity and the like.
IN3950CHN2014 2011-11-01 2012-10-31 IN2014CN03950A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011240167 2011-11-01
PCT/JP2012/078128 WO2013065720A1 (en) 2011-11-01 2012-10-31 Ophthalmological aqueous composition

Publications (1)

Publication Number Publication Date
IN2014CN03950A true IN2014CN03950A (en) 2015-10-16

Family

ID=48192065

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3950CHN2014 IN2014CN03950A (en) 2011-11-01 2012-10-31

Country Status (5)

Country Link
US (1) US9173945B2 (en)
JP (2) JP6313599B2 (en)
CA (1) CA2853235A1 (en)
IN (1) IN2014CN03950A (en)
WO (1) WO2013065720A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853235A1 (en) * 2011-11-01 2013-05-10 Rohto Pharmaceutical Co., Ltd. Ophthalmological aqueous composition
JP2016185940A (en) * 2014-06-10 2016-10-27 ロート製薬株式会社 Ophthalmic composition
JP2017197526A (en) * 2016-04-22 2017-11-02 ロート製薬株式会社 Ophthalmic composition
JP7387835B2 (en) * 2016-04-22 2023-11-28 ロート製薬株式会社 Ophthalmic composition
JP2017197524A (en) * 2016-04-22 2017-11-02 ロート製薬株式会社 Ophthalmic composition
JP7125250B2 (en) * 2016-04-22 2022-08-24 ロート製薬株式会社 ophthalmic composition
WO2017183714A1 (en) * 2016-04-22 2017-10-26 ロート製薬株式会社 Ophthalmic composition
JP7159501B1 (en) * 2016-04-22 2022-10-24 ロート製薬株式会社 ophthalmic composition
US11583496B2 (en) 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
JP6983361B2 (en) * 2019-04-26 2021-12-17 参天製薬株式会社 Ophthalmic products and their use
TW202320815A (en) * 2021-09-30 2023-06-01 日商樂敦製藥股份有限公司 Ophthalmological composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916625D0 (en) * 1989-07-20 1989-09-06 Bryce Smith Derek Respiratory tract spray preparations
JP4748289B2 (en) 2000-06-23 2011-08-17 ライオン株式会社 Eye drops, ophthalmic composition, and adsorption suppression method
JP2003146892A (en) * 2001-11-08 2003-05-21 Rohto Pharmaceut Co Ltd Cleaning agent
JP4718160B2 (en) 2003-11-12 2011-07-06 ロート製薬株式会社 Ophthalmic composition
US20050137166A1 (en) * 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
JP5403850B2 (en) * 2004-06-08 2014-01-29 ロート製薬株式会社 Ophthalmic refreshing composition
US7629386B2 (en) 2004-08-26 2009-12-08 Bausch + Lomb Incorporated Compositions containing trialkanolamine alkoxylate buffer
JP4953650B2 (en) 2005-02-09 2012-06-13 ロート製薬株式会社 Planoprofen-containing composition
WO2007077783A1 (en) * 2005-12-27 2007-07-12 Lion Corporation Composition for soft contact lens and adsorption suppressing method
EP2066300B2 (en) 2006-09-28 2019-01-23 Novartis Ag Self-preserved aqueous pharmaceutical compositions
JP5314349B2 (en) * 2007-07-25 2013-10-16 ロート製薬株式会社 Ophthalmic composition
WO2009035034A1 (en) 2007-09-14 2009-03-19 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
WO2009061431A2 (en) * 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
JP2008189677A (en) * 2008-03-10 2008-08-21 Rohto Pharmaceut Co Ltd Washing agent
JP5670200B2 (en) * 2008-12-02 2015-02-18 ロート製薬株式会社 Ophthalmic composition
JP4777477B2 (en) 2009-09-30 2011-09-21 ロート製薬株式会社 Eye drops
CA2853235A1 (en) * 2011-11-01 2013-05-10 Rohto Pharmaceutical Co., Ltd. Ophthalmological aqueous composition

Also Published As

Publication number Publication date
JPWO2013065720A1 (en) 2015-04-02
JP6242998B2 (en) 2017-12-06
WO2013065720A1 (en) 2013-05-10
US20140308368A1 (en) 2014-10-16
JP6313599B2 (en) 2018-04-18
US9173945B2 (en) 2015-11-03
JP2017052804A (en) 2017-03-16
CA2853235A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
IN2014CN03950A (en)
PH12015500730A1 (en) Inhibitors of histone demethylases
MY172926A (en) Tetrahydropyrazolopyrimidine compounds
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
WO2012071411A3 (en) Nk cell modulating treatments and methods for treatment of hematological malignancies
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
MX2014001218A (en) Treatment of breast cancer.
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
MX2015015356A (en) Stabilized pemetrexed preparation.
WO2013017967A3 (en) Antimicrobial cleansing compositions
JO3154B1 (en) Trpv4 antagonists
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3037092A4 (en) Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer or metastasis
MX2015011359A (en) Macrocyclic lrrk2 kinase inhibitors.
PH12014501140B1 (en) Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder
MX2015012526A (en) Macrocyclic rip2 kinase inhibitors.
PH12015502241A1 (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
EP3104861A4 (en) Bifunctional compounds and use for reducing uric acid levels
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
IN2014MN02484A (en)
EP3247704A4 (en) Bifunctional compounds and use for reducing uric acid levels
PL2560632T3 (en) Compounds provided with antioxidant activity against free radicals, and cosmetic compositions containing them
WO2012173382A3 (en) Skin composition for external use containing tanshinone ii a as active ingredient
WO2011113785A3 (en) A cosmetic composition for rejuvenating skin appearance
MX2013008635A (en) Improvements in and relating to compositions.